We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+2%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$339M
AUM Growth
+$36.2M
Cap. Flow
+$31.5M
Cap. Flow %
9.29%
Top 10 Hldgs %
40.44%
Holding
118
New
22
Increased
42
Reduced
29
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$9.37M
2
LH icon
Labcorp
LH
+$7.04M
3
JNJ icon
Johnson & Johnson
JNJ
+$6.49M
4
BDX icon
Becton Dickinson
BDX
+$5.83M
5
UHS icon
Universal Health Services
UHS
+$5.72M

Top Sells

Rank Stock Value
1
AMSG
Amsurg Corp
AMSG
+$5.97M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$5.94M
3
HOLX
Hologic
HOLX
+$5.76M
4
CYH icon
Community Health Systems
CYH
+$4.33M
5
CAH icon
Cardinal Health
CAH
+$4.22M

Sector Composition

Rank Sector Weight
1 Healthcare 89.84%
2 Financials 0.85%
3 Technology 0.78%
4 Real Estate 0.25%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDX icon
1
Becton Dickinson
BDX
$45.6B
$19M 5.6%
137,207
+42,230
+44% +$5.83M
AGN
2
DELISTED
Allergan plc
AGN
$17.7M 5.21%
58,166
+8,900
+18% +$2.65M
LH icon
3
Labcorp
LH
$25B
$14.2M 4.19%
136,179
+67,629
+99% +$7.04M
TMO icon
4
Thermo Fisher Scientific
TMO
$213B
$14.1M 4.17%
108,950
+4,700
+5% +$613K
GMED icon
5
Globus Medical
GMED
$10.7B
$14M 4.13%
544,839
-52,014
-9% -$1.32M
BCR
6
DELISTED
CR Bard Inc.
BCR
$12.3M 3.64%
72,299
+27,900
+63% +$4.77M
STJ
7
DELISTED
St Jude Medical
STJ
$11.9M 3.52%
163,414
+55,883
+52% +$4.04M
MRK icon
8
Merck
MRK
$322B
$11.5M 3.4%
212,016
+167,156
+373% +$9.37M
UHS icon
9
Universal Health Services
UHS
$10.2B
$11.2M 3.3%
78,575
+45,700
+139% +$5.72M
TEVA icon
10
Teva Pharmaceuticals
TEVA
$40.8B
$11.2M 3.29%
188,800
+9,300
+5% +$574K
UNH icon
11
UnitedHealth
UNH
$376B
$9.81M 2.89%
80,400
+20,800
+35% +$2.46M
MDT icon
12
Medtronic
MDT
$109B
$9.33M 2.75%
125,962
+27,000
+27% +$2.06M
JNJ icon
13
Johnson & Johnson
JNJ
$618B
$7.66M 2.26%
78,600
+64,800
+470% +$6.49M
ELV icon
14
Elevance Health
ELV
$81.5B
$6.68M 1.97%
40,675
-2,800
-6% -$447K
GILD icon
15
Gilead Sciences
GILD
$162B
$6.42M 1.89%
54,800
+21,700
+66% +$2.37M
WBA
16
DELISTED
Walgreens Boots Alliance
WBA
$6.22M 1.84%
73,700
+18,900
+34% +$1.63M
HCA icon
17
HCA Healthcare
HCA
$87.2B
$6.18M 1.82%
68,095
+25,095
+58% +$2.01M
BIIB icon
18
Biogen
BIIB
$30B
$5.7M 1.68%
14,112
+5,300
+60% +$2.13M
GI
19
DELISTED
EndoChoice Holdings, Inc.
GI
$5.37M 1.59%
+328,501
New +$5.46M
MCK icon
20
McKesson
MCK
$100B
$5.11M 1.51%
22,735
-5,800
-20% -$1.34M
SYK icon
21
Stryker
SYK
$125B
$4.92M 1.45%
51,439
+43,345
+536% +$4.11M
TNDM icon
22
Tandem Diabetes Care
TNDM
$1.34B
$4.89M 1.44%
45,125
+25,360
+128% +$3.15M
XRAY icon
23
Dentsply Sirona
XRAY
$2.68B
$4.83M 1.43%
93,700
+75,900
+426% +$3.93M
SPNC
24
DELISTED
Spectranetics Corp
SPNC
$4.71M 1.39%
204,550
+167,400
+451% +$4.68M
BHC icon
25
Bausch Health
BHC
$2.58B
$4.46M 1.32%
20,100
-1,900
-9% -$421K
1
2 3 4 5

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Endurant Capital Management held 118 positions worth $339M, up 12% from $303M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Endurant Capital Management deployed $31.5M of net new capital in Q2 2015, opening 22 new positions and adding to 42 existing holdings. Its largest new stake was EndoChoice Holdings, Inc.: 328,501 shares worth $5.37M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 88% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Amsurg Corp, an estimated $5.97M trimmed.

  • Endurant Capital Management's largest Q2 2015 buy was EndoChoice Holdings, Inc.: 328,501 shares worth $5.37M.
  • Endurant Capital Management added most to Merck in Q2 2015, an estimated $9.37M increase.
  • Endurant Capital Management's biggest Q2 2015 reduction was Amsurg Corp, cutting an estimated $5.97M.
  • Endurant Capital Management fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $5.94M.
  • Endurant Capital Management's ten largest holdings make up 40% of its $339M portfolio in Q2 2015.
  • Endurant Capital Management opened 22 new positions and closed 25 in Q2 2015.
  • Endurant Capital Management's portfolio value rose 12% quarter-over-quarter to $339M.

Based on Endurant Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.